drugset / Trial / NCT03321617
Glutamate Reducing Interventions in Schizophrenia
Phase 1
Completed
16 enrolled
New York State Psychiatric Institute
National Institute of Mental Health (NIMH) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Participants will be administered several doses of pomaglumetad (POMA) (low and high doses) over 14 days to individuals at clinical high risk for developing psychosis and use magnetic resonance imaging (MRI) brain imaging to determine whether these doses of POMA are affecting glutamate levels.
Timeline
- Start
- 2018-04-17
- Primary completion
- 2020-03-13
- Completion
- 2020-03-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2140023 | Unknown | 40 mg | — |
| Subject | LY2140023 | Unknown | 80 mg | — |
| Subject | LY2140023 | Unknown | 120 mg | — |
| Subject | LY2140023 | Unknown | 160 mg | — |
Indications
No indication recorded.